After moving 1.3% during today's evening session, Gilead Sciences is now trading at a price of $81.23 per share. On average, analysts give it a target price of $85.47.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Potential Gilead Sciences Investors Should Analyze the Following:
Gilead Sciences has moved 4.0% over the last year.
The company has a price to earnings growth (PEG) ratio of 3.05. A number between 0 and 1 could mean that the market is undervaluing Gilead Sciences's estimated growth potential
Its Price to Book (P/B) ratio is 4.79
Gilead Sciences currently returns an annual dividend yield of 3.7%.
Understanding Gilead Sciences's Operating Margins
|Date Reported||Total Revenue ($ k)||Operating Expenses ($ k)||Operating Margins (%)|